Cryo-Cell International, Inc. (CCEL) Earnings History
Annual and quarterly earnings data from 1996 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 75.2% | 10.9% | 1.3% |
| 2023 | 73.1% | -39.3% | -30.4% |
| 2022 | 71.0% | 13.3% | 9.1% |
| 2021 | 68.9% | 13.9% | 7.2% |
| 2020 | 69.0% | 24.6% | 11.6% |
Download Data
Export CCEL earnings history in CSV or JSON format
Free sign-in required to download data
Cryo-Cell International, Inc. (CCEL) Earnings Overview
As of March 1, 2026, Cryo-Cell International, Inc. (CCEL) reported trailing twelve-month net income of $399,609, reflecting +1.0% year-over-year growth. The company earned $0.05 per diluted share over the past four quarters, with a net profit margin of 0.0%.
Looking at the long-term picture, CCEL's 5-year EPS compound annual growth rate (CAGR) stands at -28.6%, signaling declining earnings. The company achieved its highest annual net income of $8M in fiscal 2015.
Cryo-Cell International, Inc. maintains positive profitability with a gross margin of 0.8%, operating margin of 0.1%, and net margin of 0.0%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including SOLV ($1.56B net income, 0.2% margin), HCSG ($40M net income, 0.0% margin), AMN (-$96M net income, -0.0% margin), CCEL has room to improve margins relative to the peer group. Compare CCEL vs SOLV →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
29 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $402,095 | +104.2% | $3M | $0.05 | 1.3% | 10.9% |
| 2023 | -$10M | -443.6% | -$12M | $-1.14 | -30.4% | -39.3% |
| 2022 | $3M | +33.0% | $4M | $0.33 | 9.1% | 13.3% |
| 2021 | $2M | -42.5% | $4M | $0.25 | 7.2% | 13.9% |
| 2020 | $4M | +58.2% | $8M | $0.45 | 11.6% | 24.6% |
| 2019 | $2M | +368.0% | $5M | $0.27 | 7.2% | 15.9% |
| 2018 | $-854,824 | -136.9% | $5M | $-0.11 | -2.9% | 17.8% |
| 2017 | $2M | +275.3% | $5M | $0.30 | 9.1% | 19.7% |
| 2016 | -$1M | -116.3% | $433,594 | $-0.16 | -5.7% | 1.9% |
| 2015 | $8M | +1364.2% | $3M | $0.83 | 38.4% | 13.9% |
See CCEL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CCEL Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CCEL vs AGIO
See how CCEL stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CCEL growing earnings?
CCEL EPS of $0.05 reflects slowing growth at +1.0%, below the 5-year CAGR of -28.6%. TTM net income is $399609.00. Expansion rate has moderated.
What are CCEL's profit margins?
Cryo-Cell International, Inc. net margin is +0.0%, with operating margin at +0.1%. Below-average margins reflect competitive or cost pressures.
How consistent are CCEL's earnings?
CCEL earnings data spans 1996-2024. The current earnings trend is +1.0% YoY. Historical data enables comparison across business cycles.